Mario Alberto Accardi

Biotech Executive. President and Founder - Orexin Program @centessa. Boards @OrthonikaMedtec @Embodyortho @g3therapeutics. Views my own.

[Medicxi @medicxi]

We are thrilled to announce positive interim Phase 1 data in acutely sleep deprived healthy volunteers for ORX750, a novel orexin receptor 2 agonist being developed by @centessa

Congratulations to Mario Accardi and the entire @centessa team for this incredible milestone

[Mario Alberto Accardi @maaccardi]

Thank you @matthorsnell !

[Matthew Horsnell @matthorsnell]

Congratulations to the @centessa Team! From @maaccardi to Dr. Debbie Hartman to Dr. Sally Black, I’m so grateful to know you!

Sending gratitude on behalf of the #narcolepsy community!

#SleepPeeps

[Centessa Pharmaceuticals @centessa]

We are thrilled to share new preclinical data for our first orexin agonist development candidate during an oral presentation at the World Sleep Congress today in Rio de Janeiro, Brazil.

Read the full press release for more details: https://t.co/quCK1IPgW7

[Centessa Pharmaceuticals @centessa]

Yesterday Centessa had the privilege of hosting a patient engagement event at our Boston headquarters to raise awareness for #narcolepsy.
A big thank you to Matt and Katie for sharing your experiences and insights - your stories are an inspiration to the Centessa team!

[Mario Alberto Accardi @maaccardi]

@Finlay_Jonny @sciencescanner @centessa Congrats Jonny and David! Exciting times ahead!

[Mario Alberto Accardi @maaccardi]

We are excited to have nominated a selective, orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. We look forward to sharing pre-clinical data at a scientific meeting later this year @centessa

[Centessa Pharmaceuticals @centessa]

This morning we announced our Q4 and Full-Year 2022 financial results and business updates. Read the full press release for more details: https://t.co/ObogLejjdc

[Medicxi @medicxi]

We are excited to announce the launch of Aldena Therapeutics to develop novel long-lasting treatments for dermatological diseases through radical new transepidermal delivery of proprietary siRNAs

[Centessa Pharmaceuticals @centessa]

Centessa is proud to sponsor @project_sleep & the Sleep Advocacy Forum on Oct. 24. Excited to connect with key sleep community leaders and hear from patient advocates who inspire our work to advance orexin agonists for the treatment of #narcolepsy. https://t.co/qVFfTugsL8

[Centessa Pharmaceuticals @centessa]

We are excited to share the first scientific poster presentation from our oral small molecule OX2R agonist program @ #SleepEurope2022. We look forward to advancing our orexin program for the treatment of #narcolepsy. View our poster @ https://t.co/HT2DhRpTg6

[Mario Alberto Accardi @maaccardi]

@matthorsnell Thank you for the kind words @matthorsnell - your energy and determination is an inspiration to our entire orexin team @centessa!

[Mario Alberto Accardi @maaccardi]

Congratulations @EmmanuelMignot8 !! #narcolepsy

[Stanford Medicine @StanfordMed]

Congratulations to long-time Stanford Medicine sleep researcher Emmanuel Mignot, MD, PhD, recipient of 2023 Breakthrough Prize in Life Sciences.
https://t.co/8D53SVR3Yu
@brkthroughprize @EmmanuelMignot8 #LifeSciences #Narcolepsy

[Mario Alberto Accardi @maaccardi]

Today is #WorldNarcolepsyDay - this day is an important occasion to raise awareness of #narcolepsy and chronic sleep disorders. It further inspires us to continue our commitment to the space as we advance our OX2R agonist program

[Centessa Pharmaceuticals @centessa]

Centessa recognizes #WorldNarcolepsyDay, a day dedicated to raising awareness & inspiring action to combat #narcolepsy. Learn how we're taking a patient-centric approach to advance novel oral small-molecule OX2R agonists for the treatment of narcolepsy: https://t.co/2fsZeSeYN5

[Project Sleep @project_sleep]

🌎✨#WorldNarcolepsyDay is hitting the Americas! 9/22/22 is dedicated to raising awareness about #narcolepsy on a GLOBAL scale. Project Sleep is proud to walk alongside you as you build a brighter future for all those living with narcolepsy! Get involved: https://t.co/CjJqTBt6dw

[Nxera Pharma @NxeraPharma]

Centessa's novel agonists were developed using structure-based design with an OX2R protein stabilized in agonist conformation using our StaR® Technology.
We are pleased to see progress of molecules designed using our technology and look forward to seeing further advancement.

[Mario Alberto Accardi @maaccardi]

Excited to showcase some non-clinical data on our orexin agonist program at Sleep Europe
@ESRS_Sleep

[Centessa Pharmaceuticals @centessa]

Today we announced a poster presentation of data from our oral small-molecule orexin receptor 2 (OX2R) agonist discovery pipeline at #SleepEurope 2022. The poster will be presented in Athens on Thurs., Sept. 29 at 12:15pm EEST. Read our press release: https://t.co/2xQ9PZUgWj

[Mario Alberto Accardi @maaccardi]

@thatgirlevolved Congrats!!🎉🚀

[Mario Alberto Accardi @maaccardi]

Great opportunity to hear from international patients discussing #narcolepsy at the @wakenarcolepsy webinar today - our CSO Deborah Hartman will also be sharing her insights into drug development

[Wake Up Narcolepsy @wakenarcolepsy]

Today is the last day to register for the International Narcolepsy Webinar being held Thursday and Friday. Hear the latest advancements from researchers, advocates and individuals with #narcolepsy from across the globe. Register Now: https://t.co/bmRFY9SIXh

[Mario Alberto Accardi @maaccardi]

Great way to start the week with our first US in person team meeting of the year! #orexia #centessa #narcolepsy #orexin #Boston

[Saurabh Saha @SaurabhSahaMD]

Significant, complimentary partnership between @centessa company, Orexia Therapeutics and @Schrodinger to accelerate the discovery of novel, differentiated orexin agonists using @Schrodinger industry-leading physics-based computational platform to supercharge Orexia's pipeline!

[Mario Alberto Accardi @maaccardi]

Excited to partner with @Schrodinger as we strengthen our commitment to OX2R agonism; while we are aiming to start IND enabling studies in 2022 we are also investing in discovery of molecules with differentiated clinical profiles to harness a broad range of indications beyond NT1

[Centessa Pharmaceuticals @centessa]

We are excited to announce Centessa company, Orexia Therapeutics, has entered into a collaboration with @Schrodinger, focused on the discovery of novel therapeutics targeting a broad spectrum of sleep disorders, including #narcolepsy. Read more here: https://t.co/306dsAjGtu